Cambridge Biotech Corp. (NASDAQ:CBCX) agreed to license DynaGen Inc.'s (NASDAQ:DYGN) technology for developing tuberculosis and other mycobacterial diagnostic products. DynaGen, of Cambridge, Mass., will supply its antigen to Worcester, Mass.-based Cambridge Biotech, which will then produce serology tests in the EIA microwell format as well as in rapid slide immunoassays. Cambridge Biotech will distribute the products worldwide. The market for TB testing devices could exceed $20 million by 1994
A synthetic form of the active ingredient in marijuana has won FDA approval for its use against the wasting effect associated with AIDS. The drug, dronabinol, helps overcome nausea and stimulate the appetite of AIDS patients, who often suffer severe weight loss. The drug is marketed by Unimed Inc. of Buffalo Grove and Roxane Laboratories Inc. of Columbus, Ohio, under the trade name Marinol. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), the main active ingredient in
Beckman Instruments Inc. of Fullerton, Calif., announced that it is one of a consortium of companies that has received a $9.23 million matching grant from the U.S. Department of Commerce to develop technologies that could speed the process of DNA analysis. the award was announced Dec. 17 by Commerce Secretary Barbara Hackman Franklin. The technology in development, called "genosensors," could increase the speed and decrease the cost of genome mapping and sequencing, making DNA analyzers
Collaborative Research Inc. (NASDAQ:CRIC) of Waltham, Mass., received a $500,000, two-year Phase II small business innovation research (SBIR) grant from the National Institute of General Medical Sciences to develop a multiplex DNA diagnostic test technology. The initial target will be for multiple mutant alleles of the CFTR gene that is responsible for cystic fibrosis. (c) 1997 American Health Consultants. All rights reserved.
Bioject Medical Systems Ltd. of Vancouver, British Columbia, and its operating subsidiary, Bioject Inc., have become wholly owned subsidiaries of newly incorporated Bioject Medical Technologies (NASDAQ:BJCT) of Portland, Ore. Each share certificate issued by Bioject Medical Systems now represents the same number of shares of common stock of Bioject Medical Technologies. (c) 1997 American Health Consultants. All rights reserved.
Curative Technologies Inc. (NASDAQ:CURE) of East Setauket, N.Y., has been awarded U.S. patent No. 5,165,938 covering wound healing agents derived from platelets. The patent covers both the autologous platelet releasate Procuren--which is on the market--and the homologous releasate CT102. (c) 1997 American Health Consultants. All rights reserved.
Biomerica Inc. (NASDAQ:BRMA) of Newport Beach, Calif., announced that it has developed an ELISA test kit for detecting thyroglobulin autoantibodies in blood samples from patients with asymptomatic chronic thyroiditis, as well as patients who have been treated for thyroid diseases such as goiter, Graves' and Hashimoto's diseases. (c) 1997 American Health Consultants. All rights reserved.
American Biogenetic Sciences Inc. (NASDAQ:MABXA) of Copiague, N.Y., has entered into a licensing arrangement with University College Dublin (UCD) and UCD faculty member Ciaran Regan to develop a new pharmaceutical agent designed to delay the progression of Alzheimer's disease. The company said that studies in lab animals have shown that the new, unnamed compound can restore the brain-damaged animals' ability to perform various memory tests. (c) 1997 American Health Consultants. All rights
The underwriters in TheraTech Inc.'s (NASDAQ:THRT) secondary offering have exercised their overallotment option for 187,500 shares, the Salt Lake City company said Tuesday. (c) 1997 American Health Consultants. All rights reserved.
CellPro Inc. announced Tuesday that the National Institutes of Health (NIH) will conduct two new human gene therapy trials -- one in patients with metastatic breast cancer and the other in patients suffering from multiple myeloma -- utilizing its stem cell concentration technology. Joyce O'Shaughnessy of the National Cancer Institute will head the breast cancer trial and Cynthia M. Dunbar of the national Heart, Lung and Blood Institute will conduct the myeloma study. The two trials will study
Vestar Inc. (NASDAQ:VSTR) of San Dimas, Calif. and Neutron Technology Corp. of Boise, Idaho, agreed to co-develop a new type of radiotherapy for treating brain cancer and AIDS- related cancers. Boron Neutron Capture Therapy involves loading cancer cells with boron, which, when exposed to a neutron beam, becomes activated and emits localized radiation that kills the cancer cells. Encapsulating boron inside liposomes allows large quantities of boron to be targeted to and concentrated within
Cambridge Biotech Corp. (NASDAQ:CBCX) agreed to license DynaGen Inc.'s (NASDAQ:DYGN) technology for developing tuberculosis and other mycobacterial diagnostic products. DynaGen of Cambridge, Mass., will supply its antigen to Cambridge Biotech of Worcester, Mass., which will then produce serology tests in the EIA microwell format, as well as in rapid slide immunoassays. Cambridge Biotech will distribute the products worldwide. The market for TB testing devices could exceed $20 million by 1994
Bio-Interfaces Inc. (BII) has sold 265,000 shares of the 330,000 shares of stock it received from Lifecore Biomedical Inc. of Chaska, Minn., as payment for Lifecore's acquisition of BII's dental implant technology. The sale of stock liquidates $2.05 million of Lifecore's debt to BII. In the original purchase transaction, the debt was scheduled to be liquidated in periodic cash payments through 1995, but the agreement was renegotiated to allow Lifecore (NASDAQ:LCBM) to substitute common stock for
Beckman Instruments Inc. of Fullerton, Calif., announced that it is one of a consortium of companies that has received a $9.23 million matching grant from the U.S. Department of Commerce to develop technologies that could speed the process of DNA analysis. The award was announced Dec. 17 by Commerce Secretary Barbara Hackman Franklin. The technology in development, called "genosensors," could increase the speed and decrease the cost of genome mapping and sequencing, making DNA analyzers
Procyte Corp. (NASDAQ:PRCY) announced an agreement with Kaken Pharmaceutical Co. Ltd. of Tokyo to develop and market Procyte's peptide-copper hair growth technology in Asia. The peptide compounds are being explored as a potential treatment for hair loss prevention and hair growth. Under the terms of the agreement, Kaken will have exclusive rights for specific peptide-copper compounds in Asia, which includes Japan, China, Taiwan, Southeast Asian countries, India and Korea. Procyte will supply
Applied Bioscience International Inc. said Tuesday that earnings per share for the fourth quarter will be about 8 cents compared with analysts' estimates of 11 to 16 cents. Kenneth H. Harper, the Arlington, Va., company's chairman, also said that Applied Bioscience intends to record restructuring charges of about $4 million, equivalent to 9 cents per share. The company will therefore report a loss of about 1 cent per share for the period. For the year, Harper said, the company anticipates
Surgeons at Duke University Medical Center used pig livers to sustain the life of a critically ill man for five days until they found a human liver for transplanting. During those five days, the patient's blood was filtered and circulated through five different pig livers via a process known as ex vivo xenoperfusion. The human liver transplant was performed on Nov. 30, and the patient is now out of critical care and doing as well as can be expected for someone who has gone through such a major
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) of San Mateo, Calif. announced that it has restructured its Singapore joint venture to give SciClone 100 percent ownership and total operating control of the venture. SciClone's partners Singapore Bio-Innovations and Transpac Capital Pte. Ltd. have converted their equity in the joint venture into 175,000 shares of SciClone's restricted common stock. (c) 1997 American Health Consultants. All rights reserved.
Genzyme Corp. (NASDAQ:GENZ) of Cambridge, Mass., has been granted two U.S. patents for producing phospholipids. Corresponding foreign applications are pending. The two patents contain claims to a salt of glycerol-3-phosphate, as well as methods for its preparation and use in the synthesis of phospholipids. (c) 1997 American Health Consultants. All rights reserved.
Seragen Inc. announced Monday that it has submitted a new drug application (NDA) with FDA to begin Phase I clinical trials on its IL-2 receptor-targeted fusion toxin in HIV-infected patients. The drug, DAB389IL-2, inhibits the replication of both lab strains of HIV-1, as well as fresh clinical isolates in cultured human lymphocytes. Researchers Lin Zhang and Clyde Crumpacker of Boston's Beth Israel Hospital reported these results in the December Journal of AIDS. Richard Svrluga, president and
Cambridge Biotech Corp. (NASDAQ:CBCX) agreed to license DynaGen Inc.'s (NASDAQ:DYGN) technology for developing tuberculosis and other mycobacterial diagnostic products. DynaGen, of Cambridge, Mass., will supply its antigen to Worcester, Mass.-based Cambridge Biotech, which will then produce serology tests in the EIA microwell format as well as in rapid slide immunoassays. Cambridge Biotech will distribute the products worldwide. The market for TB testing devices could exceed $20 million by 1994